NCT04692051 is a Phase 2 clinical trial of Nab-paclitaxel + Cisplatin in Biliary Tract Cancer, sponsored by Huazhong University of Science and Technology.

Who is sponsoring NCT04692051?

NCT04692051 is sponsored by Huazhong University of Science and Technology.

What drugs are being tested in NCT04692051?

Interventions in NCT04692051: Nab-paclitaxel + Cisplatin, Gemcitabine + Cisplatin.

What condition does NCT04692051 study?

NCT04692051 studies Biliary Tract Cancer.

Is NCT04692051 still recruiting?

NCT04692051 is currently status unknown. Last updated 31 December 2020.

Last reviewed 2020-12-31 · How we verify

NCT04692051

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Status unknown Phase 2 Last updated 31 December 2020

What this trial tests

Phase 2 trial testing Nab-paclitaxel + Cisplatin in Biliary Tract Cancer in 100 participants. Status unknown.

Timeline

1 September 2019

Primary endpoint
1 March 2021

1 September 2021

Quick facts

Lead sponsor	Huazhong University of Science and Technology
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 September 2019
Primary completion	1 March 2021
Estimated completion	1 September 2021
Sites	1 location across China

Drugs / interventions tested

Nab-paclitaxel + Cisplatin
Gemcitabine + Cisplatin — full drug profile →

Conditions studied

Biliary Tract Cancer — all drugs for Biliary Tract Cancer →

Sponsor

Huazhong University of Science and Technology

Who can join

Adults 18 to 70, any sex, with Biliary Tract Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is a trial to compare the efficacy and safety of Nab-paclitaxel plus Cisplatin vs Gemcitabine plus Cispatin as first line chemotherapy in advanced biliary tract cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Gallbladder cancer: current and future treatment options.
Zhou Y, Yuan K, Yang Y, Ji Z, et al · · 2023 · cited 40× · PMID 37251319 · DOI 10.3389/fphar.2023.1183619
Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma.
Yoo C, Hyung J, Chan SL. · · 2024 · cited 19× · PMID 38638168 · DOI 10.1159/000531458
Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial.
Yang X, Dai YH, Peng H, Zhang MS, et al · · 2025 · PMID 40819029 · DOI 10.1186/s12885-025-14581-3
Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial
Yang x, Zhuang L, Cheng Hh, Dai YH, et al · · 2025 · DOI 10.21203/rs.3.rs-5762910/v1

Verify or expand the search:

Other recruiting trials for Biliary Tract Cancer

Currently open trials in the same condition.

NCT07221253 — A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Bili · Phase 3 · recruiting
NCT06529718 — Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients · Phase 2 · recruiting
NCT07151118 — ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer · recruiting
NCT07142226 — Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC · recruiting
NCT07135544 — A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initial · Phase 2 · recruiting

Other Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07502027 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Tr · Phase 4 · not yet recruiting
NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
NCT07509866 — Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal · NA · recruiting
NCT07326943 — Minimum Effective Dose of Ropivacaine for Ultrasound-guided Interscalene Block · NA · recruiting
NCT07229976 — Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04692051 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huazhong University of Science and Technology
Last refreshed: 31 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04692051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing